Idiopathic Pulmonary Fibrosis (IPF) Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report covers the 7 major markets and provides an Excel-based forecast model for the Idiopathic Pulmonary Fibrosis (IPF) market through 2034.
GlobalData estimated that drug sales for IPF in 2024 were approximately $2.7 billion across the 7MM, with the market size anticipated to grow to approximately $5.8 billion by 2034, at a compound annual growth rate (CAGR) of 7.7%.
Major drivers of growth during the forecast period include the launches of several pipeline agents, most notably Jascayd (nerandomilast), Tyvaso (treprostinil), and admilparant, the increase in the number of diagnosed prevalent cases of IPF throughout the 7MM, the increase in the use of combination therapy and the number of patients on disease-modifying therapies.
Scope
Overview of Idiopathic Pulmonary Fibrosis (IPF), including epidemiology, symptoms, diagnosis, and disease management.
Annualized IPFtherapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the IPF therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for IPF treatment. The most promising candidates in late-stage development are profiled.
Analysis of the current and future market competition in the global IPF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the 7MM IPF therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM IPF therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Bristol-Myers Squibb
Eli Lilly
United Therapeutics
Horizon Therapeutics
Vicore Pharma
Palisade Bio
EmphyCorp
Boehringer Ingelheim
InSilico Medicine
PureTech
Roche
Mediar Therapeutics
Qureight
Endeavor BioMedicines
Transpire Bio
Suzhou Intragrand Pharma
Table of Contents
Table
Figures
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Idiopathic Pulmonary Fibrosis reports